论文部分内容阅读
目的:总结树突状细胞(dendritic cell,DC)联合细胞因子诱导的杀伤细胞(cytokine-induced killers,CIK)治疗原发性肺癌的临床疗效和护理体会。方法:对76名肺癌患者遵医嘱采用静脉回输、淋巴结区皮下注射、胸膜腔内注射途径输注DC-CIK混合培养细胞,给予相应的护理干预并观察其疗效和不良反应。结果:患者治疗后达到CR10例(13.16%),PR19例(25%),SD26例(34.21%),PD21例(26.32%),其中精神状态好转72例(94.74%),咳嗽症状减轻62例(81.58%),胸闷症状减轻48例(63.16%),体重上升5%以上35例(46.05%)。发热为出现的主要不良反应,有25例(32.89%),均为输注完毕2~4 h后出现,其中37.5~38℃者23例(30.26%),39℃以上者2例(2.63%)。结论:DC-CIK细胞治疗肺癌疗效显著,不良反应较少,患者疗中疗后生活质量相对较高。在DC-CIK细胞治疗过程中,积极给予患者心理辅导及相关知识教育,可以显著提高患者自护能力,同时在输注过程中配合医护人员的护理干预,可以有效的提高临床疗效,减少不良反应的产生,更利于患者及家属接受。
OBJECTIVE: To summarize the clinical efficacy and nursing experience of dendritic cells (DCs) combined with cytokine-induced killers (CIK) in the treatment of primary lung cancer. Methods: Sixty-six lung cancer patients were given intravenous infusion, subcutaneous injection of lymph node area and intrapleural injection of DC-CIK mixed culture cells. Corresponding nursing interventions were given and the curative effect and adverse reactions were observed. Results: CR 10 cases (13.16%), PR 19 cases (25%), SD 26 cases (34.21%) and PD 21 cases (26.32%) were cured after treatment. The improvement of mental state was 72 cases (94.74% (81.58%), relieved chest distress symptoms in 48 cases (63.16%) and weight gain in 5 (35%) cases (46.05%). There were 25 (32.89%) cases of fever with fever, of which 23 cases (30.26%) were 37.5 ~ 38 ℃ and 2 cases (2.63% ). Conclusion: The efficacy of DC-CIK cells in the treatment of lung cancer is significant, with fewer adverse reactions, and the quality of life of patients after treatment is relatively high. In the process of DC-CIK cell therapy, giving patients psychological counseling and related knowledge education can significantly improve the self-care ability of patients, meanwhile, it can effectively improve the clinical curative effect and reduce the adverse reactions during the infusion process with the nursing intervention of medical staff The more conducive to patients and their families to accept.